A B S T R A C T The binding characteristics of l-epinephrine to intact human platelets were assessed under conditions of physiological and pharmacological variations in plasma catecholamine concentration. In competition with the a2-adrenoreceptor antagonist yohimbine, mean platelet receptor affinity for l-epinephrine was decreased 3.4-fold after 2 h of upright posture and exercise. This change in agonist affinity correlated significantly with the increases in plasma epinephrine and norepinephrine that were stimulated by upright posture and exercise. Supine subjects infused with l-norepinephrine or l-epinephrine for 2 h also averaged a 3.3-and 2.7-fold decrease in platelet a2-adrenoreceptor affinity for agonist with no change in receptor number or antagonist affinity. The a2-adrenoreceptor agonist affinity changes were specific for a-agonists since they were blocked by phentolamine, and incubation with 10' M isoproterenol produced no change in a2-adrenoreceptor affinity for l-epinephrine. In vitro exposure of intact human platelets to 106 to 10-10 M l-epinephrine for 2 h produced a concentration-related decrease in a2-adrenoreceptor affinity INTRODUCTION Epinephrine acts via a2-adrenoreceptors to initiate human platelet aggregation and secretion, and to inhibit platelet adenylate cyclase activity (1) (2) (3) (4) (5) . Recently, the selective antagonist radioligand, [3H]yohimbine, has been used to characterize a2-adrenoreceptors in both intact and membrane preparations of human platelets (6) (7) (8) (9) (10) . These studies have confirmed the a2-adrenergic classification' of these platelet receptors. Further studies have identified influences of sodium and magnesium on a2-adrenoreceptor agonist binding affinity and have demonstrated high and low agonist affinity states of the receptor, which are modulated by guanine nucleotides (11) (12) (13) (14) (15) .
Exposure of platelets to high concentrations of catecholamines in vitro has been reported to decrease the number of assayable platelet a2-adrenoreceptors, either through a reduction' in receptor number or by retention of agonist in the preparation (16, 17) . Ex- posure to catecholamines at concentrations below lo-5 M has not been found to alter the number of platelet a2-adrenoreceptors (18, 19) . In vivo studies in which catecholamine concentrations range from l0' to M have yielded contradictory results. It has been reported that patients with pheochromocytoma have low or normal numbers of receptors, and patients with idiopathic orthostatic hypotension have high or normal receptor density (20) (21) (22) . No assessment of platelet a2-adrenoreceptor agonist affinity has been reported under conditions of high or low plasma catecholamines.
Recent work in our laboratory has demonstrated that variations of plasma catecholamines within the physiological range are inversely related to (3-adrenoreceptor density on human lymphocytes (23, 24) . In chronic situations, receptor density was inversely correlated with plasma catecholamine concentration. In addition, we have recently described alterations in lymphocyte (3-receptor affinity for agonist by short-term variations in plasma catecholamines (25) . This has been associated with parallel changes in the ability of isoproterenol to stimulate lymphocyte adenylate cyclase activity. Thus, changes in plasma catecholamines within the physiological range appear to modulate ,8-receptor number, agonist affinity, and sensitivity.
Our purpose in this study was to investigate the effects of physiological changes in plasma catecholamines on a2-adrenoreceptor number and agonist affinity in intact human platelets. We report here that short-term variations in plasma catecholamines within the physiological range modulate the platelet a2-adrenoreceptor's affinity for and sensitivity to agonist without changes in receptor number. (32) .
METHODS
Aggregation. Aggregation was performed on PRP by the nephelometric technique of Born (27) . Blood was drawn by the double-syringe technique into (9:1 vol) acid-citrate-dextrose and centrifuged in sealed tubes at 200 g for 20 min at room temperature. The PRP was aspirated and the remaining blood was centrifuged at 1,000 g for 10 min to obtain platelet-poor plasma. The PRP was incubated with and without various concentrations of l-epinephrine with no agitation at 25°C. Aliquots were removed at 30, 60, and 120 min and aggregatory response to l-epinephrine was determined simultaneously in epinephrine-incubated and control samples. Aggregatory response was determined graphically from the slope of the first phase of epinephrine-induced aggregation and normalized by dividing the epinephrine-incubated sample response by the control-incubated response. Variability in aggregatory response was minimized by using sealed siliconized tubes and syringes, by using each PRP sample as its own control, and by performing simultaneous control and l-epinephrine-treated aggregations. Values were tested by the pooled Chi-square test by using P < 0.01 as indication of a significant difference (28) .
Plasma catecholamine determinations were performed by a radioenzymatic assay as previously described (29) .
The Vanderbilt University Committee for the Protection of Human Subjects reviewed and approved the procedures in this study. Human subjects abstained from all medications for 14 d before these studies. All were normotensive healthy males between 20 and 38 yr of age. Posture/exercise and infusion study protocols were carried out on the Elliot V. Newman Clinical Research Center Ward.
RESULTS
Effect of posture and exercise on platelet a2-adrenoreceptor affinity and number. Table I represents the effect of overnight bedrest, 30 min of treadmill exercise, and 120 min of upright posture on plasma 12 normal subjects remained fasting at bedrest overnight in hospital before blood sampling (time 0). They then exercised on a treadmill at 75% maximal predicted heart rate (modified Bruce protocol) for 30 min before a second blood sample. The subjects remained upright and ambulatory for the ensuing 90 min for a total of 120 min of upright posture before the last blood sample. nM, mean±SEM) between the overnight and 2-h upright samples. There was no difference in platelet size distribution between the overnight supine and 2-h upright samples obtained from six of these subjects. Thus, the agonist affinity change at 120 min is not due to a change in binding site number, affinity for antagonist, or "selection" of a population of platelets with lower agonist affinity. Effect of catecholamine infusions on platelet a2-adrenoreceptor agonist binding. To ascertain whether the changes in platelet a2-adrenoreceptor agonist affinity were due to increased catecholamines, we infused l-norepinephrine or l-epinephrine intravenously into groups of seven normal subjects in the supine position after overnight bedrest. The effects of these infusions on the mean EC50, slope, and plasma catecholamines are shown in Table II .
Infusion of l-norepinephrine at 50 ng/kg per minute produced no change in EC,0 or slope after 30 min when compared with overnight bedrest. Like the exercise protocol, however, 2 h of l-norepinephrine infusion caused a significant increase in the EC50. This decrease in affinity for agonist was accompanied by Seven normal subjects remained at bedrest and fasting overnight; a blood sample was obtained (time 0) and intravenous catecholamine infusions were begun while subjects remained supine. Additional blood samples were obtained from the opposite arm at 30 and 120 min during the infusion for plasma catecholamines and l-epinephrine competition binding determinations as described in Methods and Table I . Values are expressed as mean±SEM. P < 0.05 when compared with time 0.
I P < 0.01 when compared with time 0. a shift in the slope factor toward 1.0. The l-norepinephrine infusion caused a 10-12 mmHg increase in mean blood pressure and a 5-8 beats/min decrease in heart rate. l-Epinephrine infusion at 50 ng/kg per minute showed a similar time course for changes in agonist affinity for the a2-adrenoreceptor on intact platelets. The mean slope of the Hill plots also exhibited a change toward 1.0 after 2 h of infusion. Mean blood pressure increased 2-4 mmHg and heart rate increased 10-12 beats/min during the l-epinephrine infusion.
With these catecholamine infusions, the time course and extent of receptor agonist affinity change was similar to that obtained in the posture and exercise study. In addition, they suggest that either norepinephrine or epinephrine exposure is adequate to alter a2-adrenoreceptor agonist affinity.
Effect of in vitro exposure of intact human platelets to l-epinephrine on a2-adrenoreceptor binding. In order to elucidate the dose-response relationship between catecholamines and change in a2-receptor agonist affinity, we incubated isolated, intact human platelets (obtained at 8:00 a.m. from ambulatory subjects) with varying concentrations of l-epinephrine for 2 h at 25°C. The platelets were then washed in isotonic media and competition and Scatchard binding were performed on the intact platelets in comparison with simultaneous control incubations. Table III shows the effects of 10-6_10-10 M l-epinephrine incubation on the affinity for agonist and the Hill coefficient, or slope of the Logit plot Incubation with 10-6-10-8 M l-epinephrine caused significant increases in the platelet a2-adrenoreceptor EC50 for epinephrine binding. There was also a dose-related effect on the slope factor; higher l-epinephrine concentrations caused larger shifts in the slope toward 1.0 and reached the 0.01 level of significance at 10' M epinephrine. Platelet size distribution was not affected by 2-h l-epinephrine incubations at concentrations up to 10-6 M. In additional incubations at 10' and 10-8 M l-epinephrine, there was no decline in the epinephrine concentration of the medium during the 2-h incubation.
The effects of 2 h of incubation with each concentration of l-epinephrine on antagonist binding by the a2-adrenoreceptor is shown on the right side of ber of receptors per platelet was found, despite the wide range of l-epinephrine concentrations. These findings demonstrate that the changes in agonist binding were not secondary either to altered receptor affinity for antagonist or to a change in receptor number. We also incubated platelets with the a-agonist isoproterenol, and added an a-antagonist to the l-epinephrine incubations to determine the selectivity of agonist-induced affinity changes that were measured above. Effect of in vitro exposure of platelets to 1-epinephrine on platelet aggregation induced by 1-epinephrine. To determine the physiological effects of the agonist affinity changes caused by prior agonist exposure, we incubated PRP with 10-6-10-8 M l-epinephrine at 25°C and determined l-epinephrine-induced platelet aggregation after 30, 60, and 120 min of incubation. Fig. 1 illustrates the progressive loss of aggregatory sensitivity to l-epinephrine when the first phase of aggregation is normalized to simultaneous control response. There was a time-and dose-dependent effect at both the higher l-epinephrine concentrations, while 10-8 M l-epinephrine was not significantly different from control. This agonist-mediated desensitization of the platelet a2-adrenoreceptor demonstrates that the physiological responsiveness of the platelet a2-adrenoreceptor is correlated with the receptor affinity for agonist. the agonist binding characteristics of platelet a2-adrenoreceptors without changing the total number of receptors. The affinity changes were similar in magnitude to the changes found in lymphocyte ,B-adrenoreceptor agonist affinity after the same physiological stimuli (25) . The change in the slope factor, and the positive correlation between the increase in plasma catecholamines and the increase in EG50 support the concept of an agonist-induced decrease in receptor affinity without change in number. Since 15-18 concentrations of competitive ligand are necessary to define two affinity states of receptors (33), we have confined our data analysis of ten point agonist competition binding curves to changes in EC50 and the slope factor. These represent conservative estimates of the heterogeneity in receptor agonist affinity and changes therein.
The infusion of catecholamines into supine subjects also resulted in a decrease in agonist affinity, this further supported the conclusion that catecholamine exposure causes the change in receptor affinity. These data also reduce the possibility that the changes in EC50 during the posture and exercise protocol were due to in vivo factors other than adrenergic agonist exposure.
An unexpected finding was the apparent time lag between agonist exposure and affinity change. In vitro studies of turkey erythrocyte and cultured astrocytoma cells (34, 35) , and in vivo studies of lymphocytes (25, 36) indicate that the f-adrenoreceptor shows rapid changes in affinity and sensitivity to agonist after exposure to agonists. We found little or no change in agonist binding after 30 min of in vivo exposure to levels of catecholamines that eventually resulted in affinity changes after 120 min. This suggests that there is either a concentration-time dependency for this affinity change, or that a series of events which take longer than 30 min must occur to effect changes in affinity in the platelet a2-adrenoreceptor system. Our data do not permit us to differentiate between these or other explanations for the time delay in affinity change. 2 h of in vitro exposure to l-epinephrine produced a shift in the affinity for agonists and was accompanied by proportional increases in the slope factor toward 1.0. The absolute values for EC50 in the control samples were higher than in the in vivo protocols; this was probably because the samples were obtained from volunteers who had been erect for 60-90 min. Although this reduced the fold shift obtained on incubation with l-epinephrine, the effect of in vitro exposure to agonist is still evident. Since in vivo plasma epinephrine concentrations are in the range of 0.15-0.30 nM, our in vitro conditions required somewhat higher concentrations of l-epinephrine to cause a change in EC50. This may be due, in part, to the incubation conditions, including artificial buffer, 25°C, and no stirring. However, these data still identify changes in platelet a2-adrenoreceptors at concentrations of l-epinephrine that are three orders of magnitude lower than previously reported.
Incubation of PRP with 10-6 to 10-8 M l-epinephrine illustrates the functional effect of the agonist-mediated affinity changes on subsequent aggregatory response. The higher l-epinephrine concentrations resulted in a dose-and time-dependent desensitization of aggregatory response when challenged with the same agonist. Since these aggregatory studies were carried out with simultaneous control incubations by using the same platelet sample, variations due to time-dependent pH changes, ADP, platelet factor 4, thromboxane accumulation, different platelet concentrations, and concurrent plasma catecholamine concentrations were all controlled.
Our results indicate that the time of day and the circumstances under which samples are obtained may influence the results in adrenergic agonist binding studies on circulating cellular elements. The relatively short-term changes in agonist affinity without change in receptor number are in contrast to the alterations in receptor number reported in pheochromocytoma and orthostatic hypotension (20, 21) . These discrepancies raise the possibility that short-term regulation of platelet sensitivity occurs through modulation of receptor affinity for agonist, whereas long-term sensitivity changes are mediated by alterations in receptor number.
We also considered the possibility that endogenous or exogenous catecholamines or in vitro exposure to catecholamines might involve the selection of a population of platelets which were less sensitive to adrenergic agonists (37) . This might produce the changes in agonist affinity found in our experiments. If this occurred, however, we would have expected to find fewer platelets after in vitro exposure to l-epinephrine, and/or a change in size distribution of the platelets after in vivo or in vitro exposure to catecholamines. Neither of these changes occurred.
Prior studies found reductions in platelet a2-adrenoreceptor number and function after in vitro exposure to l-epinephrine concentrations of 10-M or greater (16, 17) . These results were interpreted as showing "down-regulation" of receptor number or agonist retention by the platelet a2-adrenoreceptor. However, unlike our studies, these studies incubated platelets with high concentrations of l-epinephrine for long periods of time; yet, no data concerning platelet count or size distribution was presented. Furthermore, no significant change in receptor number or function occurred after incubation with concentrations of l-epinephrine below 1o-5 M or for less than 4 h (16, 17) . In contrast, we found a maximal effect on platelet Ca2-adrenoreceptor agonist affinity after in vitro incubation with 1lo M l-epinephrine for 2 h. Our antagonist binding studies further demonstrate that no change in number of receptors per platelet nor in receptor affinity for antagonist occurs after exposure to more physiological concentrations of catecholamines. In addition, our in vivo protocols found no change in platelet a2-adrenoreceptor agonist affinity after 30 min of exposure to elevated catecholamines. Since plasma catecholamines were highest at 30 min, our results are not compatible with the concept of a retained agonist that causes changes in receptor number or affinity for agonist.
In summary, we have found [3H]yohimbine to be a specific, rapid, saturable, and reversible ligand for the identification of a2-adrenoreceptors on intact human platelets. Endogenous and exogenous catecholamines can reduce the affinity of the intact platelet a2-adrenoreceptor for agonist without a change in receptor number. In vitro exposure of intact platelets to epinephrine results in a rapid loss of sensitivity to epinephrine-induced aggregation and a dose-related reduction in a2-adrenoreceptor affinity for agonist. These observations demonstrate acute regulation of intact human platelet a2-adrenoreceptor's affinity for and sensitivity to agonist by endogenous and exogenous catecholamines.
